N-Hydroxy-3-[1-(phenylthio)methyl-1H-1,2,3-triazol-4-yl]benzamide (NCC-149), developed by Suzuki, Miyata
et al., selectively inhibits histon deacetylase 8 (HDAC8). Histon deacetylase (HDAC) regulates gene expression, such as the tumor-suppressor gene, by catalyzing the deacetylation reaction of the acetylated lysine residue in histon. HDAC8, an isoform of histon deacetylase, has been reported to be implicated in T-cell lymphomas and neuroblastoma tumorigenesis. It is expected that NCC-149 will be used as an epigenetics research tool and an anticancer agent because of its selective inhibitory activity of HDAC8 and tumor cell growth.